Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
THMR is like that creepy relative you can't wait to say goodbye to after an uncomfortable holiday visit.
in CTIC. thx for alerts (CADX nice)
CADX news! CEO Sees $600M-$800M Acetavance Mkt
NEW YORK (Dow Jones)--Shares of Cadence Pharmaceuticals Inc. (CADX) continued rising a day after the company reported positive results from a Phase III study of its lead drug, and the company's chief executive said Thursday in an interview that he expects a potential $600 million to $800 million market for Acetavance. Cadence President and Chief Executive Ted Schroeder told Dow Jones Newswires Thursday that the trial of Acetavance, an intravenous formulation of acetaminophen to treat acute pain following abdominal laparoscopic surgery, wasn't pivotal for the submission of a new drug application to the U.S. Food and Drug Administration. "The reason we performed the trial was really to study the alternative dosing," Schroeder said. "What we realized is there are a fair number of U.S. physicians who only use acetaminophen at the 650mg per dose level...Having a lower dose gives flexibility to a physician to prescribe an IV in the same way they would prescribe an oral drug." Shares closed Thursday up 7.8% to $6.90 after ending up 28% Wednesday. Cadence said Wednesday that the clinical trial revealed that Acetavance shows a statistically significant reduction in pain intensity when compared to a placebo. The company said the drug also was safe and effective in a lower dose. Schroeder said Acetavance has a potentially large market opportunity due to the size of unmet medical need in treating pain in adults and children who can't take painkillers by mouth. He added that U.S. physicians currently have two choices of painkiller: IV narcotics, such as morphine; or ketorolac, a non-steroidal anti-inflammatory drug that interferes with blood clotting. "Physicians will now have the opportunity to treat with a safer and effective drug that allows them to use less narcotics and provide equal or better pain relief," Schroeder said. Schroeder estimated potential sales of Acetavance to be $600 million to $800 million a year based on sales figures of the drug by Bristol-Myers Squibb Co. (BMY) in Europe. Cadence plans to file an NDA with the FDA in the second quarter with hopes of a drug-launch in mid-2010. The company also intends to submit an NDA for its second drug in the second quarter. The drug, Omigard, is a topical antimicrobial gel for the prevention of catheter-related infections. Schroeder said the company is looking to acquire additional products. "We're always looking, but I wouldn't say there's a transaction imminent," he said. Schroeder also said the company hasn't found it difficult to fund the trials because it secured financing before market conditions worsened. "The issue that we could face moving forward is we will need to do additional financing prior to commercializing the product," Schroeder said. "It certainly will be more difficult going forward than in the past due to the overall decline in the stock market." Schroeder added that the company has a variety of options for financing and that Cadence isn't concerned about securing financing. "But it will be more difficult," he said.
XL - get out while you can - just downgraded
calling bottom @ .0000
U.S. mortgage applications up 2.9% (THMR!)
CADX is going to be red hot according to folks I know in biotech research. IV Tylenol in every hospital..
CADX great news - been loading on dips
I just swallowed my puke...time to sign off and avoid after hours in this place. LOL
i_like_bb_stock and Ogclip © = $$$$$$$$ (IMHO)
You'll learn about others when you lose or gain your first $100K quietly hanging out here.
GNTA .003 finally (watching carefully)
Can't see L2 on this one. Flying blind.
Needs more volume...hoping for .30 break this week
Still respect (and act on) MANY opinions posted by a select few on this BBoard ... knowing the game, following the right players and ignoring the children has been key.
Now everybody focus on making $$$$$$
Understood. Thanks for speaking up.
You mean the one who spread rumor of AIG R/S yesterday? Let him join GNOTE thankfully now banned.
when GNTA finally hits .003 will the world come to an end or what..can't resist those stacked bids unless I'm missing something.?
FirstFED taking a beating today - 52w low 1.75 - not sure I want to touch it though
THMR buying opp before FED moves
Liars now ignored - should be banned.
I'll retract if so called R/S and T/O come to pass.
Trust in BB integrity fading......too bad
No response huh?
XL 4.20 ... nice gain from 2.90
XL is a $12 stock on sale under $4 but not for long. Stupid selling created a major opp. Close as I'll get to pumping anything.
XL Insurance Company Ltd Receives Court Approval for Merger with XL Europe Ltd
8:57a ET December 9, 2008 (PR NewsWire)
XL Insurance, the global insurance operations of XL Capital Ltd (NYSE: XL), today announced that the English High Court in London has approved the merger of XL Europe Ltd (Dublin) into XL Insurance Company Ltd (London).
This order follows the approval of the business portfolio transfer from XL Europe Ltd to XL Insurance Company Ltd by the Irish High Court in Dublin on 4 December 2008.
The portfolio transfer and merger are due to take effect from 31 December 2008 and form the culmination of a year-long project to restructure and streamline XL Insurance's operations into a single platform to serve the countries of the European Economic Area as well as Asia and Australia. XL London Market Limited's Lloyd's based business is unaffected by this change.
David Duclos, Chief Executive Officer at XL Insurance, said: "The Court approval for the merger of XL Insurance Company Ltd and XL Europe Ltd represents the final step in this long-term project. This cross-border merger of insurance companies is the first of its kind in the UK and Ireland, following the recent implementation of the European Union's Merger Directive. It involved close co-ordination between our underwriters, compliance, legal and finance experts while keeping our clients and brokers informed. The project started in 2007 and follows the successful restructuring of XL's reinsurance segment in Europe two years ago.
"We believe that a single, streamlined European and Australasian insurance platform will be better placed to serve our business requirements and the needs of clients and their brokers. We expect the simplified structure to improve capital efficiency and put us in a strong position for Solvency II."
XL Insurance Company Ltd is registered in London and regulated by the Financial Services Authority (FSA). The merged company has capital and surplus of just under $1 billion.
Not a sick Co - just had several mergers. Unjustified panic selloff on news - should bounce at least 2x from here by Fri.
XL major $$$ opp at this level
XL falling like a rock today..
ANVH Expands Potential Revenue by an Estimated $20 Million
Concur..all equity holders wiped out. Managed to sell my last few hundred shares at 1.40 as news broke but made a ton over last week so no complaints. (Still a great BBoard by the way!) Later.
thx..was nice while it lasted.
hmmm. CNBC reported "FDIC to seize WAMU & sell deposits to JPM for undisclosed sum".
Siezed by FDIC...fat lady singing
careful with AIG...heading to at least 2.50
Hank is just bitter..will probably sell down under $2.50 before next nice bounce...just a hunch
AIG's Greenberg Intends To Sell Stock For Liquidity Purposes
ICBS, McCoy Enterprises LLC, Connell Associates LLC enter into joint health care venture in 11 billion dollar industryLast update: 3/11/2008 11:28:00 AMNJ, CARY NC and MONTREAL, March 11, 2008 /PRNewswire-FirstCall via COMTEX/ -- ICBS Limited (Pink Sheets :ICBM) a business development and management firm located in New York and Canada and McCoy Enterprises LLC of New Jersey, a life science product development company, and Connell Associates LLC of Cary NC, a Pharmaceutical and Biotechnology Consulting organization announced today that they have entered into a joint venture under the name of PharmaDerm LLC. PharmaDerm LLC will be focused on licensing, developing and commercializing their portfolio of pharmaceutical and biotechnologies. Pharmaderm will work with the US Food and Drug Administration (FDA) and The Health Protection Branch of Canada to gain regulatory approval of products for commercialization of new treatments for Skin Disorders, Chronic Wounds, Severe Burns, Dermatology. Connell Associates, LLC is a Pharmaceutical and Biotechnology consulting company and has helped launch over 25 major drugs. They are in the Sales Management, Marketing and commercial consulting arena. "PharmaDerm LLC will be the perfect match to utilize the specific expertise of the corporations." Says Joe Connell, President and CEO of Connell Associates, LLC. "McCoy Enterprises, LLC is proud to be part of this multi-national venture to bring quality products to the people who need them" says Randall McCoy, President of McCoy Enterprises, LLC. "The strength brought in by Connell Associates and ICBS, Limited ensures success of commercializing proven products." ICBS specializes in mergers and acquisitions (M&A) advisory services and invests in selective businesses with potential for high growth." This joint venture has brought together a perfect team to take advantage of this vast market" said Garth McIntosh, President & CEO of ICBS. NB. This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of any number of factors, including the risk factors contained in the Company's disclosure documents.
Is STNL still on your radars?
NYSE Euronext:Arca Edge Begins Trading Pink Sheet Securities
ISML Estimates New Revenue Potential at $3 to $4 Million
ISM International Inc. Announces Accelerated Interest in GotchaGPS Technology - Estimates New Revenue Potential at $3 to $4 MillionLast update: 2/12/2008 5:33:01 PMDUNEDIN, Fla., Feb 12, 2008 (BUSINESS WIRE) -- ISM International Inc. (Pink Sheets:ISML) today announced accelerated interest in its GotchaGPS technology. ISM Chief Executive Officer Mario Quenneville says, "Two large trucking fleets have inquired about the GotchaGPS technology. We have the technical capability to offer services specifically tailored to the needs of individual fleets. As a result of these conversations, we are looking to provide GotchaGPS to at least 1,200 vehicles across USA. This could generate approximately $3 to 4 million in new revenues." Quenneville adds, "In addition, we are currently working with countries allied with the United States to add our GotchaGPS to their surveillance systems. This includes the maritime industry where the possibilities are particularly exciting." About ISM International: ISML () is a consolidation of business professionals, engineers, technologists and entrepreneurs who have formed a diversified public company designed to enhance value for shareholders through innovation and technology. SOURCE: ISM International Inc.
SHZ alert
SHZ hit AMEX and going up nicely